- Stocks
- Healthcare
- NASDAQ: SAGE

Price (delayed)

$71.15

Market cap

$4.16B

P/E Ratio

5.71

Dividend/share

N/A

EPS

$12.46

Enterprise value

$3.28B

The net income has surged by 199% year-on-year and by 5% since the previous quarter

SAGE's quick ratio has soared by 163% YoY and by 4.7% QoQ

SAGE's equity has soared by 136% YoY but it is down by 3.3% from the previous quarter

What are the main financial stats of SAGE

Market
Valuations
Earnings

Shares outstanding

58.48M

Market cap

$4.16B

Enterprise value

$3.28B

Price to earnings (P/E)

5.71

Price to book (P/B)

2.07

Price to sales (P/S)

3.73

EV/EBIT

5.15

EV/EBITDA

5.12

EV/Sales

2.95

Revenue

$1.11B

EBIT

$637.05M

EBITDA

$641.59M

Free cash flow

$691.82M

Per share
Balance sheet
Liquidity

EPS

$12.46

Free cash flow per share

$11.85

Book value per share

$34.31

Revenue per share

$19.08

TBVPS

$35.64

Total assets

$2.08B

Total liabilities

$77.42M

Debt

$22.72M

Equity

$2B

Working capital

$1.99B

Debt to equity

0.01

Current ratio

33.09

Quick ratio

32.74

Net debt/EBITDA

-1.37

Margins
Efficiency
Dividend

EBITDA margin

57.6%

Gross margin

99.9%

Net margin

57.2%

Operating margin

56.7%

Return on assets

43.9%

Return on equity

46.6%

Return on invested capital

96%

Return on capital employed

31.6%

Return on sales

57.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Sage Therapeutics stock price performed over time

Intraday

2.45%

1 week

-5.22%

1 month

-5.97%

1 year

106.41%

YTD

-17.76%

QTD

-4.94%

How have Sage Therapeutics's revenue and profit performed over time

Revenue

$1.11B

Gross profit

$1.11B

Operating income

$631.34M

Net income

$637.05M

Gross margin

99.9%

Net margin

57.2%

The net income has surged by 199% year-on-year and by 5% since the previous quarter

Sage Therapeutics's operating income has soared by 194% YoY and by 6% from the previous quarter

Sage Therapeutics's operating margin has surged by 101% YoY and by 6% QoQ

The company's net margin has surged by 101% YoY and by 5% QoQ

What is Sage Therapeutics's growth rate over time

What is Sage Therapeutics stock price valuation

P/E

5.71

P/B

2.07

P/S

3.73

EV/EBIT

5.15

EV/EBITDA

5.12

EV/Sales

2.95

Sage Therapeutics's EPS has increased by 7% from the previous quarter

SAGE's equity has soared by 136% YoY but it is down by 3.3% from the previous quarter

The P/B is 66% less than the 5-year quarterly average of 6.0 and 33% less than the last 4 quarters average of 3.0

SAGE's P/S is 98% below its last 4 quarters average of 176.5

How efficient is Sage Therapeutics business performance

SAGE's ROA has soared by 178% year-on-year but it is down by 15% since the previous quarter

Sage Therapeutics's ROE has soared by 174% YoY but it has decreased by 17% from the previous quarter

Sage Therapeutics's ROS has soared by 101% YoY and by 5% from the previous quarter

The ROIC has contracted by 12% from the previous quarter

What is SAGE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SAGE.

How did Sage Therapeutics financials performed over time

SAGE's quick ratio has soared by 163% YoY and by 4.7% QoQ

The current ratio has soared by 159% YoY and by 4.8% from the previous quarter

The company's debt is 99% lower than its equity

SAGE's equity has soared by 136% YoY but it is down by 3.3% from the previous quarter

The debt to equity has plunged by 75% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.